HomeNewsBusinessMoneycontrol ResearchAurobindo Pharma: Vaccine and API plans inject add-on growth levers

Aurobindo Pharma: Vaccine and API plans inject add-on growth levers

In the injectables space, Aurobindo Pharma remains constructive and targets to almost double from current annual sales base of $380 million to $650-700 million in three years backed by new plants in the US and Vizag

Anubhav Sahu

February 12, 2021 / 11:06 IST

Aurobindo Pharma: Vaccine and API plans inject add-on growth levers

Watch Webinar

PRO Panorama

Moneycontrol Pro Panorama | Motown fills up on GST rate cuts

Sep 23, 2025 / 02:43 PM IST

In Moneycontrol Pro Panorama September 23 edition: Indian IT faces the blues with new H1B visa rule, GST cuts brought to fuel dema...
Read Now
PRO Weekender

Moneycontrol Pro Weekender | Fed cuts rates, but projections tell a murkier story

Sep 20, 2025 / 12:23 PM IST

The Fed's latest 25 basis point cut met expectations, but the mixed economic forecasts and market reactions point to an environmen...
Read Now

Unlock This Article

Are you a PRO subscriber? Sign In

What Do You Get

Ad free Experience

Seamless navigation, faster responses.
Expert Perspective

Explore 230+ exclusive editorials every month
+

Uncover Insights from World-Renowned Experts and Journalists
Actionable Insights

40+ weekly investment ideas + 3 to 4 daily technical calls
Virtual Events

Exclusive Live Webinars for Expert Trading & Investment Strategies!
Newsletters

Stay ahead with daily and weekly insights

View Offers

Unlock exclusive discounts

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More